Also listed on Genoa Corporation, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Apr 24, 2032 · High confidence
20-year base term ends Jan 31, 2032
Held by Avalyn Pharma Inc.
Filed Jan 31, 2012 as application 13/363,311 · Granted Oct 9, 2018
Base term plus 842 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2012
2032
Clock starts
Jan 31, 2012
Jan 31, 2012
Term ends
Apr 24, 2032
Apr 24, 2032
Granted
Oct 9, 2018
Oct 9, 2018
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
842
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 10,105,356, US 9,770,443.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 842 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 31, 2012, when this application, 13/363,311, was filed | Jan 31, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +842 days, USPTO patent term adjustment record | May 22, 2034 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,105,356, US 9,770,443) | capped to Apr 24, 2032 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Apr 24, 2032 | High confidence |
This family
| US 10,092,552 | this patent Apr 2032 | Apr 2032 |
| US 10,105,356 | In force Apr 2032 | Apr 2032 |
| US 11,224,592 | In force Jan 2032 | Jan 2032 |
| Application 16/167,337 | Abandoned not computed | not computed |
| US 11,452,718 | In force Jan 2032 | Jan 2032 |
| US 11,559,520 | In force Jan 2032 | Jan 2032 |
| Application 17/576,830 | Pending not computed | not computed |
| US 12,226,407 | In force Jan 2032 | Jan 2032 |
8 of 9 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 17, 2012 Reel 28061, frame 864 | Surber, Mark William | Genoa Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Oct 24, 2017 Reel 44597, frame 756 | Genoa Pharmaceuticals, Inc. | Avalyn Pharma Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Apr 2032
Term ends Apr 24, 2032. Maintenance fees still fall due before then
Note
The 842 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,105,356, US 9,770,443.
Citations
52
later US patents cite this one
That is top 5% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.